iPath Pure Beta S&P GSCI-Weighted ETN
SBV
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- United States of America
- IPO Date
- May 16, 2017
- Website
- barclaysinvestments.co.uk
- Similar Companies
- Business
- Barclays Bank PLC issues the iPath® Pure Beta S&P GSCI®-Weighted ETN (SBV), an exchange-traded note (ETN) that provides investors exposure to the S&P GSCI Weighted Pure Beta Index; this index tracks futures contracts on a diversified basket of commodities including energy, agriculture, livestock, industrial metals, and precious metals, offering a cash payment at maturity, early redemption, or issuer call based on the index's performance less fees. The ETN, listed on U.S. exchanges such as NYSE Arca, targets institutional and retail investors seeking commodities-linked returns without direct futures trading. Barclays Bank PLC, headquartered in London, UK, and founded in 1690, operates its iPath ETNs series globally through Barclays Capital Inc. as distribution agent, with primary activities in investment banking and structured products across North America, Europe, and Asia. Within the commodities segment of the exchange-traded products industry, SBV focuses on pure beta replication of broad commodity market volatility and weighting, distinguishing it from cap-weighted benchmarks. The product suite includes related iPath ETNs covering specific commodities or strategies, such as energy or agriculture-focused variants. In June 2025, Barclays exercised its issuer call option to redeem SBV in full on June 25, 2025, following a cash tender offer and consent solicitation that amended the indenture to enable full redemption, with valuation on June 17, 2025, and cash payments to remaining holders based on the closing indicative value. This action terminated trading and investor redemption rights for SBV, reflecting Barclays' ongoing portfolio optimization of legacy iPath ETNs amid low outstanding amounts. No recent partnerships, funding rounds, acquisitions, or new product launches specific to SBV were announced in 2024 or 2025, though Barclays continues consultations on index methodologies for other iPath series.